Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Am J Ophthalmol. 2018 Aug;192:91-97. doi: 10.1016/j.ajo.2018.05.014. Epub 2018 May 23.
To investigate whether having macular fluid on optical coherence tomography (OCT) prior to cataract surgery adversely affected vision or anatomic outcomes after cataract surgery in patients with exudative age-related macular degeneration (AMD).
Retrospective cohort study.
We examined all patients who underwent cataract surgery and were receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections from January 1, 2012 through December 31, 2016. There were 81 eyes that underwent cataract surgery and had received at least 1 intravitreal anti-VEGF injection for a diagnosis of exudative AMD within 6 months prior to surgery. Data collected included the development of subretinal or intraretinal macular fluid, or subretinal hemorrhage, in the 6 months following surgery; number of injections; best-corrected visual acuity (BCVA); and central subfield thickness (CST).
There was a significant improvement between preopertive and postoperative BCVA when comparing all patients (P values < .0001) and no significant difference in CST before and after surgery (P > .05). There were 23 eyes with fluid on the preoperative OCT. There were no differences in final BCVA or CST and no difference in the development of fluid postoperatively when compared to patients without fluid preoperatively (all P values > .05). These patients also saw a significant improvement in BCVA (P = .006).
In a real-world setting, patients with both cataracts and wet AMD may safely undergo cataract surgery. Patients with stable preoperative fluid on OCT should be considered for cataract surgery, as these patients did well postoperatively, with no worsening of their neovascular process.
研究在接受白内障手术前光学相干断层扫描(OCT)上有黄斑积液的渗出性年龄相关性黄斑变性(AMD)患者,其白内障手术后视力或解剖结果是否受到不良影响。
回顾性队列研究。
我们检查了所有在 2012 年 1 月 1 日至 2016 年 12 月 31 日期间接受白内障手术并接受玻璃体内抗血管内皮生长因子(anti-VEGF)注射的患者。有 81 只眼接受了白内障手术,并在手术前 6 个月内接受了至少 1 次玻璃体内抗 VEGF 注射,以诊断为渗出性 AMD。收集的数据包括手术后 6 个月内是否出现视网膜下或视网膜内黄斑积液或视网膜下出血;注射次数;最佳矫正视力(BCVA);和中央视网膜神经纤维层厚度(CST)。
所有患者的术前和术后 BCVA 均有显著改善(P 值均<.0001),手术前后 CST 无显著差异(P>.05)。术前 OCT 有 23 只眼有积液。与术前无积液的患者相比,最终 BCVA 或 CST 无差异,术后积液的发展也无差异(所有 P 值均>.05)。这些患者的 BCVA 也有显著改善(P=.006)。
在真实环境中,同时患有白内障和湿性 AMD 的患者可以安全地接受白内障手术。对于 OCT 上有稳定术前积液的患者,应考虑行白内障手术,因为这些患者术后表现良好,新生血管过程无恶化。